Shares of Atlas Arteria Limited (OTCMKTS:MAQAF – Get Free Report) traded down 16.3% on Tuesday . The stock traded as low as $3.08 and last traded at $3.08. 200 shares changed hands during trading, a decline of 84% from the average session volume of 1,235 shares. The stock had previously closed at $3.68.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. Royal Bank Of Canada cut Atlas Arteria to an “underperform” rating and set a $4.75 price target for the company. in a research note on Thursday, July 2nd. Jefferies Financial Group upgraded Atlas Arteria to a “buy” rating and set a $5.31 price target on the stock in a research note on Thursday, August 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Atlas Arteria presently has an average rating of “Hold” and a consensus price target of $5.03.
Get Our Latest Research Report on MAQAF
Atlas Arteria Trading Down 16.3%
About Atlas Arteria
Atlas Arteria (OTCMKTS: MAQAF) is a global toll road owner and operator specializing in the development, management and long-term investment of transport infrastructure. The company partners with governments and institutional investors to acquire, manage and optimise concession-based road assets, generating stable revenue streams through user fees and toll collections. Atlas Arteria focuses on enhancing traffic flow and safety through targeted capital improvements and operational efficiencies across its portfolio.
The company’s primary assets span North America, Europe and Australia.
See Also
- Five stocks we like better than Atlas Arteria
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Atlas Arteria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Arteria and related companies with MarketBeat.com's FREE daily email newsletter.
